Overview

GnRH Antagonist Pre-treatment in the Early Follicular Phase for Resolution of a Baseline Functional Ovarian Cyst

Status:
Recruiting

Trial end date:
2023-03-01

Target enrollment:
0

Participant gender:
Female

Summary

In this study we would like to examine the effect of GnRH antagonist administration at the beginning of the follicular phase in patient presenting with a simple ovarian cyst 25-50 mm. The aim of this intervention is to allow a spontaneous regression of the ovarian cyst (if in nature) while ensuring a pituitary downregulation to prevent the beginning of a leading follicle recruitment. As previous studies using GnRH antagonist pre-treatment prior to GT initiation for other purposes demonstrated positive results (including different patient population) , no deleterious effects are expected.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Assaf-Harofeh Medical Center

Treatments:

Cetrorelix

Criteria

Inclusion Criteria:

1. Antagonist protocol.

2. Presentation for cycle initiation on day 2-3 of the menstrual cycle with a simple
ovarian cyst >25 mm and < 50mm, and estradiol levels < 220 pmol/L.

Exclusion Criteria:

1. Inability to provide informed consent.

2. Oocyte donor